ONO-8577

ONO-8577 is a small molecule antagonist of the Prostaglandin E2 receptor 3 (EP3), currently under development by Ono Pharmaceutical for the treatment of overactive bladder (OAB). Prostaglandin E2 (PGE2) is a key mediator in bladder sensory signaling; activation of EP3 receptors located on sensory nerves and detrusor smooth muscle is thought to contribute to the symptoms of urgency and frequency associated with OAB. By selectively blocking these receptors, ONO-8577 aims to suppress detrusor overactivity and improve bladder storage symptoms. It represents a novel therapeutic approach compared to traditional anticholinergics and beta-3 adrenergic agonists, potentially offering a different safety and efficacy profile for patients who are refractory to or intolerant of existing treatments.